Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) Michael SandherrMarcus HentrichOliver A. Cornely Original Article Open access 21 July 2015 Pages: 1441 - 1450
Prediction of central venous catheter–related bloodstream infections (CRBSIs) in patients with haematologic malignancies using a modified Infection Probability Score (mIPS) Enrico SchalkLynn HanusFlorian H. Heidel Original Article 03 May 2015 Pages: 1451 - 1456
Desmopressin improves platelet function in uremic patients taking antiplatelet agents who require emergent invasive procedures Ji Hyun KimChung Hee BaekHyosang Kim Original Article 03 May 2015 Pages: 1457 - 1461
Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban Oliver KönigsbrüggePeter QuehenbergerCihan Ay Original Article 30 May 2015 Pages: 1463 - 1471
Headache prevalence following recovery from TTP and aHUS Jennifer N. SaultzHaifeng M. WuSpero Cataland Original Article 11 June 2015 Pages: 1473 - 1476
HES1 activation suppresses proliferation of leukemia cells in acute myeloid leukemia Chen TianYong YuYizhuo Zhang Original Article 21 June 2015 Pages: 1477 - 1483
Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines Dae Sik KimKa-Won KangByung Soo Kim Original Article 06 May 2015 Pages: 1485 - 1492
Aberrant germinal center formation, follicular T-helper cells, and germinal center B-cells were involved in chronic graft-versus-host disease Liang ShaoAlbert K. W. LieYok-Lam Kwong Original Article 12 May 2015 Pages: 1493 - 1504
Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease Yinuo WangXiaosu ZhaoJun Wan Original Article 09 June 2015 Pages: 1505 - 1514
The extent of local tumor invasion predicts prognosis in stage IE nasal natural killer/T-cell lymphoma: a novel T staging system for risk stratification Xi-wen BiWen-wen ZhangWen-qi Jiang Original Article 01 May 2015 Pages: 1515 - 1524
Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma Xi-wen BiYi XiaZhi-ming Li Original Article 10 May 2015 Pages: 1525 - 1533
High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma, nasal type Hua WangPengfei LiZhiMing Li Original Article 21 May 2015 Pages: 1535 - 1544
Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma Semra PaydasEmine BağırMelek Ergin Original Article 26 May 2015 Pages: 1545 - 1552
Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice M. BeckerB. TschechneL. Straßl Original Article Open access 28 June 2015 Pages: 1553 - 1558
Hospital population screening reveals overrepresentation of CD5− monoclonal B-cell lymphocytosis and monoclonal gammopathy of undetermined significance of IgM type Minna VoigtlaenderBirthe VoglerMascha Binder Original Article 05 June 2015 Pages: 1559 - 1565
Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT İlknur AkHasan OnnerOlga Meltem Akay Original Article 13 June 2015 Pages: 1567 - 1575
Trained clinical nurse specialists proficiently obtain bone marrow aspirates and trephine biopsies in a nearly painless procedure—a prospective evaluation study M. NaegeleL. LepplaM. Engelhardt Original Article 02 June 2015 Pages: 1577 - 1584
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms N. PolverelliL. CataniF. Palandri Letter to the Editor 16 May 2015 Pages: 1585 - 1587
Severe sustained hypoplastic bone marrow after immunosuppressive therapy in malignant lymphoma cases with anti-centromere protein-B antibody Rie TabataChiharu TabataMasaru Kojima Letter to the Editor 13 May 2015 Pages: 1589 - 1591
Synchronous Hodgkin’s lymphoma and schwannomas mimicking refractory Hodgkin’s lymphoma Onno C. LeeksmaRick L. M. HaasAart Brutel de la Rivière Letter to the Editor 31 May 2015 Pages: 1593 - 1595
Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report Alessandro LucchesiPier Paolo FattoriMariasanta Napolitano Letter to the Editor 09 June 2015 Pages: 1597 - 1598
A novel MYH9 mutation in a patient with MYH9 disorders and platelet size-specific effect of romiplostim on macrothrombocytopenia Jun YamanouchiTakaaki HatoMasaki Yasukawa Letter to the Editor 09 June 2015 Pages: 1599 - 1600
Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro Satoshi ImanishiRyoko TakahashiJunko H. Ohyashiki Letter to the Editor 06 June 2015 Pages: 1601 - 1602
Localized LECT2 amyloidosis of the adrenal gland with coexisting MGUS: a diagnostic challenge Trevor E. AngellAbhisek SwaikaSikander Ailawadhi Letter to the Editor 07 June 2015 Pages: 1603 - 1604
Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma Chan Yoon CheahRobert Z. OrlowskiThein H. Oo Letter to the Editor 05 June 2015 Pages: 1605 - 1607
Negative PET: no guarantee of good prognosis in Hodgkin’s lymphoma Hugo J. A. AdamsThomas C. Kwee Letter to the Editor 14 June 2015 Pages: 1609 - 1610
Evidence-based reflection on the value of FDG-PET for interim and end-of-treatment response assessment in diffuse large B-cell lymphoma Hugo J. A. AdamsThomas C. Kwee Letter to the Editor 12 June 2015 Pages: 1611 - 1613
Analysis of survival by tumor response: have we learnt any better? Gabriele IhorstJohannes WaldschmidtMonika Engelhardt Letter to the Editor 24 June 2015 Pages: 1615 - 1616
Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia Marko LucijanicRuzica Lasan-TrcicOzren Jaksic Letter to the Editor 20 June 2015 Pages: 1617 - 1619